US MFN Drug Pricing: What Changed Between 2025 and 2026?
US MFN pricing has moved from political ambition to deals and draft rules. What has changed, why Medicare timelines look uncertain, and what to model next.
Read articleNews and Insights
Golden Triangle Consultants at World EPA Congress 2026
Golden Triangle Consultants will attend the World Evidence, Pricing and Access Congress 2026 in Amsterdam on 3–4 March.
Read articleCould US Reboot Signal the Value Based Pricing Tipping Point?
Value-based pricing may be entering a new phase as high-cost advanced therapies, outcomes-based agreements and changing evidence capabilities challenge traditional pricing models.
Read articleSaudi HTA July 2025: Gulf & Global Pricing Implications
Saudi Arabia’s move towards mandatory economic evaluation adds a value-based layer to a market already influential through IRP and Gulf procurement.
Read articleCanada Finalises PMPRB Drug Pricing Rules: Key Takeaways
Canada’s PMPRB published its updated Guidelines in June 2025, marking a significant shift in how staff identify patented medicines for potential excessive-price review.
Read articleGlobal Ripple Effects of the U.S. “MFN” Pricing Order
The May 2025 US Most-Favoured-Nation drug-pricing order has implications that extend into global launch sequencing, list-price strategy and international reference pricing.
Read articleEU HTA Goes Live: What the JCA Means for Access, Pricing & IRP
The EU HTA Regulation began applying in January 2025, introducing Joint Clinical Assessments for oncology medicines and advanced therapies and changing evidence planning across Europe.
Read articleBracing for 22.9%: What the 2025 VPAG Payback Rate Means
The 2025 VPAG headline payment percentage for eligible newer medicines was set at 22.9%, creating significant forecasting and UK launch-strategy considerations.
Read articleGTC Returns to EPA
Golden Triangle Consultants returned to the World Evidence, Pricing and Access Congress in Amsterdam in 2024.
Read articleAI vs. Health Economists: Can ChatGPT Build Budget Impact Models?
An early practical experiment testing whether ChatGPT could guide the construction of a simple pharmaceutical budget impact model in Excel.
Read articleAI-Generated Content in Pharmaceuticals: A Cautionary Tale
An early experiment with generative AI highlighted both the impressive fluency of AI-generated pharmaceutical content and the serious risk of fabricated evidence and references.
Read articleGolden Triangle Consultants at EPA 2023
Golden Triangle Consultants attended the World Evidence, Pricing and Access Congress 2023 in Amsterdam.
Read article